Project Grant R15HL177713
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $590K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
- This Project Grant award of $777,258 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to advance the understanding of heart failure in hypertrophic cardiomyopathy (HCM) and evaluate the impact of the cardiac myosin inhibitor mavacamten compared to surgical myectomy. The research, to be conducted by Beth Israel Deaconess Medical Center, Inc. from February 2025 through January 2030, will utilize cardiac magnetic resonance imaging...
- This $713,511 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research into the impact of myosin-binding protein C (MyBP-C) on myosin mobility and proteostasis in the context of hypertrophic cardiomyopathy (HCM). The University of Vermont & State Agricultural College, the awardee, will utilize innovative techniques to investigate how reduced MyBP-C levels, a common cause of HCM, may disrupt normal heart...
- The Project Grant award titled "STRUCTURE, FUNCTION AND DRUG TREATMENT OF THE NATIVE CARDIAC SARCOMERE IN HYPERTROPHIC CARDIOMYOPATHY" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $149,804. The award aims to utilize advanced cryo-electron tomography (cryo-ET) imaging techniques to directly observe how hypertrophic cardiomyopathy (HCM)-causing mutations and the HCM drug mavacamten affect the structure and function of...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The primary objectives are to: 1) fully characterize at the atomic level three specific functional domains of the cardiac thin filament linked to the...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $730,764 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Case Western Reserve University (CWRU) to conduct research on the molecular basis for cardiac myosin binding protein C (cMyBP-C) variants that cause hypertrophic cardiomyopathy (HCM). The project aims to utilize cryo-electron microscopy and other techniques to define how cMyBP-C missense variants affect cardiac sarcomere structure and...
- This Project Grant award, valued at $667,704.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to address hypertrophic cardiomyopathy (HCM), a genetic heart condition affecting 1 in 500 adults. The primary objective is to develop chemically inducible split base editors (SBE) that can precisely and controllably edit the MYBPC3 gene in the heart to correct mutations that cause HCM. The research aims to expand...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Washington. The goal of this 2-year award is to establish a system to accelerate the reclassification of variants of unknown significance in the MYH7 gene, which cause hypertrophic cardiomyopathy, and determine the role of genetic modifiers that influence the severity of this disease. The research will utilize human induced pluripotent...
- This Project Grant award for $727,710.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to advance understanding of the mechanisms driving arrhythmogenic cardiomyopathy, a genetic heart disease that can cause sudden death in young people. The award supports research at the University of California, San Diego (UCSD) to develop preclinical mouse models exhibiting inflammation and T-cell mediated immune responses as key drivers of this...
- The University of Arizona, operating as the Arizona Board of Regents, was awarded a $125,385 Project Grant on June 15, 2025 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of mutation-specific calmodulin kinase II (CaMKIID) activation in hypertrophic cardiomyopathy (HCM). The project aims to elucidate the specific biophysical alterations in the cardiac thin filament that trigger increased autonomous CaMKIID activity in...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $708,265 in funding to Weill Medical College of Cornell University from September 1, 2025 through June 30, 2029. The research project aims to expand understanding of how fibroblast growth factor homologous factors (FHFs) influence cardiac physiology and how genetic variants contribute to arrhythmias, providing a platform for targeted therapies. Key research objectives...